Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-10-04 Sale |
2024-10-08 6:54 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
2,825 | $27.51 | $77,704 | 191,085 (Indirect Direct) |
View |
| 2024-10-01 Sale |
2024-10-03 6:47 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
527 | $27.54 | $14,512 | 1,077,409 (Indirect) |
View |
| 2024-10-01 Sale |
2024-10-03 6:45 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
526 | $27.54 | $14,485 | 1,048,729 (Indirect) |
View |
| 2024-10-01 Sale |
2024-10-03 6:44 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
521 | $27.54 | $14,347 | 192,358 (Direct) |
View |
| 2024-10-01 Sale |
2024-10-03 6:43 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
518 | $27.54 | $14,264 | 193,910 (Indirect Direct) |
View |
| 2024-09-27 Sale |
2024-10-01 7:53 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $24.61 | $153,829 | 387,758 (Direct) |
View |
| 2024-09-16 Sale |
2024-09-18 4:17 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $22.41 | $28,458 | 194,428 (Indirect Direct) |
View |
| 2024-08-29 Sale |
2024-09-03 5:43 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $22.49 | $269,841 | 1,077,936 (Indirect) |
View |
| 2024-08-27 Sale |
2024-08-29 6:36 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $22.54 | $95,782 | 199,129 (Direct) |
View |
| 2024-08-26 Sale |
2024-08-28 7:48 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $22.89 | $274,718 | 1,049,255 (Indirect) |
View |
| 2024-08-15 Sale |
2024-08-19 7:49 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $23.25 | $29,526 | 195,698 (Indirect Direct) |
View |
| 2024-07-31 Sale |
2024-08-02 7:26 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
3,099 | $27.56 | $85,399 | 1,089,936 (Indirect) |
View |
| 2024-07-31 Sale |
2024-08-02 7:25 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
2,270 | $27.56 | $62,555 | 1,061,255 (Indirect) |
View |
| 2024-07-31 Sale |
2024-08-02 7:23 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
991 | $27.53 | $27,281 | 203,379 (Direct) |
View |
| 2024-07-31 Sale |
2024-08-02 7:22 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
2,351 | $27.5 | $64,663 | 196,968 (Indirect Direct) |
View |
| 2024-07-29 Sale |
2024-07-31 7:33 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $26.7 | $320,378 | 1,093,035 (Indirect) |
View |
| 2024-07-29 Sale |
2024-07-31 7:31 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $26.68 | $140,052 | 204,370 (Direct) |
View |
| 2024-07-25 Sale |
2024-07-29 5:39 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $24.92 | $299,073 | 1,240,587 (Indirect) |
View |
| 2024-07-15 Sale |
2024-07-17 7:25 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $24.8 | $31,497 | 199,319 (Indirect Direct) |
View |
| 2024-07-12 Sale |
2024-07-16 5:37 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
50,000 | $25.06 | $1,252,826 | 344,027 (Indirect) |
View |
| 2024-07-12 Sale |
2024-07-16 5:34 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,000 | $25.07 | $75,195 | 209,620 (Direct) |
View |
| 2024-07-01 Sale |
2024-07-03 4:31 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $22.89 | $274,736 | 1,105,035 (Indirect) |
View |
| 2024-06-27 Sale |
2024-07-01 8:03 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $22.57 | $95,922 | 212,620 (Direct) |
View |
| 2024-06-25 Sale |
2024-06-27 4:35 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $21.66 | $259,902 | 1,252,587 (Indirect) |
View |
| 2024-06-17 Sale |
2024-06-20 7:20 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $21.48 | $27,278 | 200,589 (Indirect Direct) |
View |
| 2024-06-06 Sale |
2024-06-10 6:46 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
1,133 | $20.06 | $22,722 | 447,369 (Indirect Direct) |
View |
| 2024-05-29 Sale |
2024-05-31 4:05 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $21.73 | $260,800 | 1,323,585 (Indirect Direct) |
View |
| 2024-05-28 Sale |
2024-05-30 5:56 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $23.18 | $278,210 | 1,453,428 (Indirect Direct) |
View |
| 2024-05-28 Sale |
2024-05-30 5:54 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $23.18 | $98,530 | 216,870 (Direct) |
View |
| 2024-05-16 Sale |
2024-05-20 7:46 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $23.74 | $30,150 | 201,859 (Indirect Direct) |
View |
| 2024-05-16 Sale |
2024-05-20 5:03 pm |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
1,033,300 | $22.14 | $22,877,262 | 7,663,349 (Indirect) |
View |
| 2024-05-16 Sale |
2024-05-20 5:00 pm |
Enliven Therapeutics Inc. | ELVN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director 10% Owner |
1,033,300 | $22.14 | $22,877,262 | 7,663,349 (Indirect) |
View |
| 2024-05-14 Sale |
2024-05-16 7:29 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
1,107 | $25 | $27,675 | 448,502 (Indirect Direct) |
View |
| 2024-05-09 Sale |
2024-05-13 7:35 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
260 | $25.06 | $6,515 | 449,609 (Indirect Direct) |
View |
| 2024-05-06 Sale |
2024-05-08 8:40 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
4,875 | $22.72 | $110,769 | 449,869 (Indirect Direct) |
View |
| 2024-05-03 Sale |
2024-05-07 6:58 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $22.5 | $22,500 | 221,120 (Direct) |
View |
| 2024-04-29 Sale |
2024-05-01 7:04 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $17.92 | $214,988 | 1,335,585 (Indirect Direct) |
View |
| 2024-04-29 Sale |
2024-05-01 7:02 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $16.97 | $55,165 | 222,120 (Direct) |
View |
| 2024-04-25 Sale |
2024-04-29 6:50 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $16.89 | $202,700 | 1,465,428 (Indirect Direct) |
View |
| 2024-04-11 Sale |
2024-04-15 7:06 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
17,500 | $25.03 | $438,099 | 454,744 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-10-01 Exercise |
2024-10-03 6:44 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
521 | $2.48 | 192,358 (Direct) |
View |
| 2024-10-01 Exercise |
2024-10-03 6:44 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
521 | $0 | 192,358 (Direct) |
View |
| 2024-09-27 Exercise |
2024-10-01 7:53 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $2.48 | 387,758 (Direct) |
View |
| 2024-09-27 Exercise |
2024-10-01 7:53 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
6,250 | $0 | 387,758 (Direct) |
View |
| 2024-08-27 Exercise |
2024-08-29 6:36 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $2.48 | 199,129 (Direct) |
View |
| 2024-08-27 Exercise |
2024-08-29 6:36 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $0 | 199,129 (Direct) |
View |
| 2024-07-31 Exercise |
2024-08-02 7:23 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
991 | $2.48 | 203,379 (Direct) |
View |
| 2024-07-31 Exercise |
2024-08-02 7:23 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
991 | $0 | 203,379 (Direct) |
View |
| 2024-07-29 Exercise |
2024-07-31 7:31 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $2.48 | 204,370 (Direct) |
View |
| 2024-07-29 Exercise |
2024-07-31 7:31 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
5,250 | $0 | 204,370 (Direct) |
View |
| 2024-07-12 Exercise |
2024-07-16 5:34 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,000 | $2.48 | 209,620 (Direct) |
View |
| 2024-07-12 Exercise |
2024-07-16 5:34 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,000 | $0 | 209,620 (Direct) |
View |
| 2024-06-27 Exercise |
2024-07-01 8:03 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $2.48 | 212,620 (Direct) |
View |
| 2024-06-27 Exercise |
2024-07-01 8:03 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $0 | 212,620 (Direct) |
View |
| 2024-06-06 Exercise |
2024-06-10 6:46 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
1,133 | $2.48 | 447,369 (Direct) |
View |
| 2024-06-06 Exercise |
2024-06-10 6:46 pm |
N/A 2031-03-25 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
1,133 | $0 | 447,369 (Direct) |
View |
| 2024-05-29 Exercise |
2024-05-31 4:05 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $1.12 | 1,323,585 (Direct) |
View |
| 2024-05-29 Exercise |
2024-05-31 4:05 pm |
N/A 2030-06-16 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $0 | 1,323,585 (Direct) |
View |
| 2024-05-28 Exercise |
2024-05-30 5:56 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $1.12 | 1,453,428 (Direct) |
View |
| 2024-05-28 Exercise |
2024-05-30 5:56 pm |
N/A 2030-06-16 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $0 | 1,453,428 (Direct) |
View |
| 2024-05-28 Exercise |
2024-05-30 5:54 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $2.48 | 216,870 (Direct) |
View |
| 2024-05-28 Exercise |
2024-05-30 5:54 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
4,250 | $0 | 216,870 (Direct) |
View |
| 2024-05-14 Exercise |
2024-05-16 7:29 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
1,107 | $2.48 | 448,502 (Direct) |
View |
| 2024-05-14 Exercise |
2024-05-16 7:29 pm |
N/A 2031-03-25 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
1,107 | $0 | 448,502 (Direct) |
View |
| 2024-05-09 Exercise |
2024-05-13 7:35 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
260 | $2.48 | 449,609 (Direct) |
View |
| 2024-05-09 Exercise |
2024-05-13 7:35 pm |
N/A 2031-03-25 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
260 | $0 | 449,609 (Direct) |
View |
| 2024-05-06 Exercise |
2024-05-08 8:40 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
4,875 | $2.48 | 449,869 (Direct) |
View |
| 2024-05-06 Exercise |
2024-05-08 8:40 pm |
N/A 2031-03-25 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
4,875 | $0 | 449,869 (Direct) |
View |
| 2024-05-03 Exercise |
2024-05-07 6:58 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $2.48 | 221,120 (Direct) |
View |
| 2024-05-03 Exercise |
2024-05-07 6:58 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
1,000 | $0 | 221,120 (Direct) |
View |
| 2024-04-29 Exercise |
2024-05-01 7:04 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $1.12 | 1,335,585 (Direct) |
View |
| 2024-04-29 Exercise |
2024-05-01 7:04 pm |
N/A 2030-06-16 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $0 | 1,335,585 (Direct) |
View |
| 2024-04-29 Exercise |
2024-05-01 7:02 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 222,120 (Direct) |
View |
| 2024-04-29 Exercise |
2024-05-01 7:02 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 222,120 (Direct) |
View |
| 2024-04-25 Exercise |
2024-04-29 6:50 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $1.12 | 1,465,428 (Direct) |
View |
| 2024-04-25 Exercise |
2024-04-29 6:50 pm |
N/A 2030-06-16 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel PRESIDENT AND CEO |
12,000 | $0 | 1,465,428 (Direct) |
View |
| 2024-04-11 Exercise |
2024-04-15 7:06 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
14,903 | $2.48 | 454,744 (Direct) |
View |
| 2024-04-11 Exercise |
2024-04-15 7:06 pm |
N/A 2031-03-25 |
Enliven Therapeutics Inc. | ELVN | Patel Anish CHIEF OPERATING OFFICER |
14,903 | $0 | 454,744 (Direct) |
View |